Last reviewed · How we verify

Serum thyroglobulin level — Treatment Landscape & Competitive Intelligence

Serum thyroglobulin level (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Serum thyroglobulin level, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Thyrogen THYROTROPIN ALFA Sanofi Adrenocorticotropic Hormone [EPC] Thyrotropin receptor 1953-01-01
Thyrogen Thyrogen National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Recombinant human thyrotropin Thyrotropin receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 1 drug in Serum thyroglobulin level
  2. Sanofi · 1 drug in Serum thyroglobulin level

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Serum thyroglobulin level:

Cite this brief

Drug Landscape (2026). Serum thyroglobulin level — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/serum-thyroglobulin-level. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing